Recent evidence supports a role for glutamate receptors in the pathophysiology of multiple sclerosis. In the present study, we have focused speci®cally on the expression of metabotropic glutamate receptors (mGluRs) in multiple sclerosis brain tissue. The expression of group I (mGluR1a and mGluR5) and group II (mGluR2/3) mGluRs was studied using immunohistochemistry in tissue from 12 multiple sclerosis cases and seven nonneurological controls. The expression patterns of both group I and II mGluRs in multiple sclerosis tissue differed signi®cantly from those in control tissue. Strong mGluR1a immunoreactivity was observed in axons of the subcortical white matter, particularly in the centre of actively demyelinating lesions and in the borders of chronic active lesions. mGluR1a axonal immunopositivity was also found in normal appearing multiple sclerosis white matter, but axons in control white matter were generally negative. mGluR1a axonal labelling was associated with the presence of non-phosphorylated neuro®laments and b-amyloid precursor protein, which are sensitive markers for axonal injury and disturbed axonal transport. Changes in mGluR immunoreactivity were also observed in glia. A diffuse increase in the expression of mGluR5 and mGluR2/3 was detected in reactive astrocytes in multiple sclerosis lesions. However, only a subpopulation of reactive astroglial cells expressed mGluR1a. In addition, labelling with antibodies to mGluR2/3 and, to a lesser extent labelling with antibodies to mGluR1a, was detected in a population of cells of the microglial/macrophage lineage that displayed a macrophage-like morphology. Our data suggest that mGluRs, like ionotropic glutamate receptors, play a role in the complex processes that are associated with the progressive brain damage in multiple sclerosis, including both glial activation and pathological changes in axons.
Summary
Recent evidence supports a role for glutamate receptors in the pathophysiology of multiple sclerosis. In the present study, we have focused speci®cally on the expression of metabotropic glutamate receptors (mGluRs) in multiple sclerosis brain tissue. The expression of group I (mGluR1a and mGluR5) and group II (mGluR2/3) mGluRs was studied using immunohistochemistry in tissue from 12 multiple sclerosis cases and seven nonneurological controls. The expression patterns of both group I and II mGluRs in multiple sclerosis tissue differed signi®cantly from those in control tissue. Strong mGluR1a immunoreactivity was observed in axons of the subcortical white matter, particularly in the centre of actively demyelinating lesions and in the borders of chronic active lesions. mGluR1a axonal immunopositivity was also found in normal appearing multiple sclerosis white matter, but axons in control white matter were generally negative. mGluR1a axonal labelling was associated with the presence of non-phosphorylated neuro®laments and b-amyloid precursor protein, which are sensitive markers for axonal injury and disturbed axonal transport. Changes in mGluR immunoreactivity were also observed in glia. A diffuse increase in the expression of mGluR5 and mGluR2/3 was detected in reactive astrocytes in multiple sclerosis lesions. However, only a subpopulation of reactive astroglial cells expressed mGluR1a. In addition, labelling with antibodies to mGluR2/3 and, to a lesser extent labelling with antibodies to mGluR1a, was detected in a population of cells of the microglial/macrophage lineage that displayed a macrophage-like morphology. Our data suggest that mGluRs, like ionotropic glutamate receptors, play a role in the complex processes that are associated with the progressive brain damage in multiple sclerosis, including both glial activation and pathological changes in axons.
Introduction
Multiple sclerosis is a chronic demyelinating disease of the CNS, which primarily affects young adults and in most cases leads to chronic disability. Little is known yet about the pathogenesis of the disease. Several hypotheses have been proposed, including viral infection and autoimmunity (Meinl, 1999; Noseworthy, 1999; Lucchinetti et al., 2000; Simmons, 2001; Gutierrez et al., 2002; Levin et al., 2002) . Recent studies have suggested a possible role for glutamate excitotoxicity in the pathophysiology of this disease (for a review see Matute et al., 2001) . Patients with multiple sclerosis were found to have increased CSF levels of excitatory amino acids (Stover et al., 1997; Barkhatova et al., 1998) , and alterations in glutamate homeostasis have been observed in multiple sclerosis lesions (Werner et al., 2001 ). In addition, correlations between altered glutamate homeostasis and oligodendrocyte and axonal damage have been reported in animals with experimental autoimmune encephalomyelitis (EAE, an animal model for multiple sclerosis) (Matute et al., 1999 (Matute et al., , 2001 Werner et al., 2001 ). Oligodendroglial cells have been shown to be highly vulnerable to glutamate-mediated toxicity both in vitro and in vivo (Matute et al., 1997; McDonald et al., 1998) . This, together with the observation that treatment with a speci®c glutamate receptor antagonist results in a substantial improvement of the disease in animals with EAE (McDonald et al., 1998) , strongly supports the involvement of glutamate and its receptors in the pathogenesis of demyelinating disorders.
Previous studies have focused speci®cally on the role of ionotropic glutamate receptors, which are ligand-gated ion channels [including N-methyl-D-aspartate (NMDA), kainate and a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors] in the pathogenesis of multiple sclerosis (Matute, 1998; Pitt et al., 2000; Paul and Bolton, 2002) . However, the cell-speci®c distribution and the role of metabotropic glutamate receptors (mGluRs) in multiple sclerosis tissue have not yet been de®ned. mGluRs consist of at least eight subtypes and they regulate a variety of intracellular signalling systems via activation of GTP-binding proteins (Pin and Duvoisin, 1995; Schoepp et al., 1999) . They are subdivided into three main groups. Group I includes mGluR1 and -5, which are coupled to phosphoinositide hydrolysis, while group II (mGluR2 and -3) and group III (mGluR4, -6, -7 and -8) mGluRs are negatively coupled to adenylyl cyclase (Schoepp et al., 1999) .
Depending on the receptor subtype, mGluRs are localized at the postsynaptic and/or presynaptic sites of neuronal elements, as well as in glial cells (Cartmell and Schoepp, 2000) . Neuronal mGluRs are thought to play important roles in synaptogenesis and synaptic plasticity, and also in several pathophysiological processes (for reviews see Miller et al., 1995a; Bordi and Ugolini, 1999) . The neuronal localization of mGluRs to the somato-dendritic and/or axonal compartments is particularly interesting in relation to the morphological and functional axonal changes described in multiple sclerosis (Ferguson et al., 1997; Trapp et al., 1998 ; for a review see Kornek and Lassmann, 1999) . Axonal injury in multiple sclerosis has been demonstrated within active lesions, in association with activation of microglia/macrophages and astroglia, and in normal-appearing white matter (NAWM) (Giordana et al., 2002; Rieckmann and Maurer, 2002) .
Glial cells also express mGluR subtypes (Romano et al., 1995; Petralia et al., 1996; Biber et al., 1999; Aronica et al., 2000 Aronica et al., , 2001a Taylor et al., 2002) . The astroglial expression of both group I and II subtypes appears to be dynamic, with expression levels changing in response to different types of brain injury in vivo (Boxall et al., 1996; Ulas et al., 2000; Aronica et al., 2000 Aronica et al., , 2001a Ferraguti et al., 2001 ) and upon exposure of cultured astrocytes to growth factors (Miller et al., 1995b; Minoshima and Nakanishi, 1999; Aronica et al., 2002) . Several observations suggest that glial mGluRs can regulate glial function and may be involved in the interaction between glia and neurons in both physiological and pathological conditions (Chiu and Kriegler, 1994; Ciccarelli et al., 1997; Agrawal et al., 1998; Bruno et al., 1998; McGeer and McGeer, 1998; Aronica et al., 2002; Taylor et al., 2002) . Moreover, glial mGluRs may play a role in neuroin¯amma-tory disorders as speci®c mGluR agonists have the ability to regulate the production of chemokines RANTES by astrocytes in vitro and to improve the rate of functional recovery from EAE in vivo (Besong et al., 2002) .
In the present study, immunocytochemistry with antibodies (Abs) speci®c for mGluR1a, mGluR2/3 and mGluR5 was performed on post-mortem control and multiple sclerosis brain samples. Our aim was to de®ne the possible involvement of mGluR in the pathophysiology of multiple sclerosis, and increase the knowledge on the role of excitotoxicity in this disease.
Material and methods

Subjects and tissue
Tissues from the 12 multiple sclerosis and seven control cases that were used in this study were obtained from of the Departments of Pathology of the Vrije Universiteit (VU) Medical Center and the Academic Medical Center (University of Amsterdam) and from the Netherlands Brain Bank (coordinator, R. Ravid). The Netherlands Brain Bank received permission to perform autopsies, for the use of tissue and for access to medical records for research purposes from the Ethical Committee of the VU Medical Center, Amsterdam, The Netherlands. Patients were rapidly autopsied and tissue samples were selected on the basis of postmortem MRI. The tissue samples used in this study were selected on the basis of the presence of both white and cortical grey matter in the section. Most of the samples had at least one multiple sclerosis lesion in or in the proximity of the grey matter. Areas of NAWM were also selected. All cases were reviewed independently by two neuropathologists. The diagnosis of multiple sclerosis and the classi®cation of the lesions followed the previously described histopathological criteria (van der Valk and De Groot, 2000) . The classi®cation of the lesions was based on extensive analysis of the distribution of in¯ammatory cells, T cells, macrophages and astrocytes, and on the presence of active myelin breakdown, as previously reported (van der Valk and De Groot, 2000; Hulshof et al., 2002) . The clinical features (derived from patients' medical records) of the multiple sclerosis and controls subjects are summarized in Table 1 .
Tissue preparation
Paraf®n-embedded tissue was sectioned at 5 mm and mounted on organosilane (3-aminopropylethoxysilane; Sigma Chemical Company, St Louis, MO) coated slides. Representative sections of all specimens were processed for standard haematoxylin±eosin and Luxol Fast Blue staining, as well as for immunocytochemical reactions using a number of neuronal and glial markers described below. Sequential sections of 5 mm were also used to study the distribution of neuro®laments, vimentin, glial ®brillary acidic protein (GFAP) and mGluRs within the same specimen. For indirect immuno¯uorescence labelling studies, multiple sclerosis material was ®xed in a solution of 4% paraformaldehyde in phosphate-buffered saline (PBS; pH 7.4), for 1±7 days at 4°C and then incubated in a solution of 30% sucrose for 1±3 days at 4°C under constant rotation (Wolswijk, 1998 (Wolswijk, , 2002 . The tissue subsequently was placed in a boat prepared from aluminium foil containing Tissue-Tek OCT embedding compound (Sakura Finetek Europe BV, Zoeterwoude, The Netherlands), frozen on dry ice and stored at ±80°C. Sections (10 mm thick) were cut from each tissue block using a Reichert±Jung 2800 cryostat (cutting temperature: ±25°C), mounted onto SuperFrost*/Plus microscope slides (Menzel-Gla Èser, Germany), stored at ±20°C and then immunolabelled using indirect immuno¯uorescence techniques, as described below.
Antibody characterization
Abs against GFAP (polyclonal rabbit, DAKO A/S, Glostrup, Denmark; 1 : 2000; monoclonal mouse, Chemicon International, Inc., Temecula, CA, 1 : 50), vimentin [monoclonal Ab (mAb), clone V9, DAKO; 1 : 100], human leukocyte antigen (HLA)-DP, DQ, DR (mAb IgG 1 ; DAKO, 1 : 300), myelin oligodendrocyte glycoprotein (MOG; the Z12 IgG 2a mAb, 1 : 300; a generous gift of Dr L. Diemel; Piddlesden et al., 1993) , neuro®laments (mAb clone 2F11, DAKO, 1 : 500; mAb clone RT97 IgG 1 , 1 : 300, Chemicon; mAb SMI-32, IgG 1 , 1 : 300, Sternberger Monoclonals, Inc., MD) and b-amyloid precursor protein (anti-b-APP mAb; Boehringer Mannheim, Germany; 5 mg/ml) were used in the routine immunocytochemical analysis to document the presence of reactive gliosis and axonal damage in the multiple sclerosis tissue. The SMI-32 antibody (against non-phosphorylated neuro®lament) provides a sensitive marker for axonal pathological changes (Trapp et al., 1998) . In normal and lesion areas, resting astrocytes were distinguished from reactive astrocytes on the basis of their morphology and the absence of vimentin immunoreactivity (IR), as previously reported (Khurgel and Ivy, 1996; Aronica et al., 2000) .
For the detection of mGluRs, we used Abs speci®c for the mGluR subtypes 1a, 2/3 (polyclonal rabbit, Chemicon; 1 : 100) and 5 (polyclonal rabbit, Upstate Biotech, Lake Placid, NY, 1 : 100). Characterization of these Abs in human brain tissue has been documented previously (Aronica et al., 2001a, b) . The Ab speci®city was tested by pre-incubating the Abs with 100-fold excess of the antigenic peptides and by western blots of the total homogenates of human control brain. 
Immunohistochemistry
For single-label immunocytochemistry, sections were deparaf®nated in xylene, rinsed in descending concentrations of ethanol (100, 97 and 70%) and incubated for 20 min with 1% H 2 O 2 diluted in methanol. Slides were then washed with PBS (10 mM, pH 7.4). The slides were placed into sodium citrate buffer (0.01 M, pH 6.0) and heated for 10 min in a microwave oven (650 W), with the exception of immunolabellings involving GFAP. The slides were allowed to cool for 20 min in the same solution at room temperature and then washed in PBS. They were incubated with a mixture of 10% normal goat serum (NGS), for 1 h prior to the incubation with the primary Ab (30 min at room temperature and at 4°C overnight). Sections were then washed thoroughly with PBS and incubated at room temperature for 1 h with the appropriate biotinylated secondary Ab diluted in PBS (1 : 400 goat-anti rabbit Ig or 1 : 200 goat-anti mouse Ig; DAKO). Single-label immunocytochemistry was carried out using an avidin±biotin peroxidase method (Vector Elite) with 3,3¢-diaminobenzidine (DAB) as a chromogen. Sections were counterstained with haematoxylin, dehydrated in alcohol and xylene and coverslipped. Sections incubated without the primary Ab or with pre-immune sera were essentially blank.
Immuno¯uorescence labelling studies were carried out on 5 mm thick paraf®n-embedded tissue and on 10 mm thick cryostat sections cut from 4% paraformaldehyde-®xed tissue blocks, as described in detail previously (Wolswijk, 1998 (Wolswijk, , 2002 . Sections were incubated for 3 days at 4°C in the primary Ab solutions (diluted in Tris-buffered saline containing 0.125% Triton X-100 and 2.5% heat-inactivated calf serum), rinsed several times in Tris-buffered saline (pH 7.6) and then incubated for 2 days at 4°C with the¯uorochrome [¯uorescein isothiocyanate (FITC) or Cy3]-conjugated or biotinylated anti-rabbit or anti-mouse Ig subclass-speci®c Abs (1 : 200; purchased from either Southern Biotechnology Associates, Inc., Birmingham, AL, or Jackson ImmunoResearch, West Grove, PA). The binding of the biotinylated Abs was visualized by incubating sections for 2 days at 4°C in the presence of the Cy5-coupled streptavidin (1 : 100; Vector Laboratories,). Sections were viewed on a Zeiss Axiophot microscope equipped with phase-contrast, Nomarski, bright®eld and dark-®eld optics, epi-UV illumination and selective ®lters optimized for distinguishing between FITC, Cy3 and Cy5 emission, or on a Zeiss 410 inverted confocal laser scanning microscope equipped with lasers emitting at 488, 543 and 633 nm to excite FITC, Cy3 and Cy5, respectively.
Evaluation of immunostaining
All labelled tissue sections were evaluated by two independent observers, with respect to the presence or absence of various histopathological parameters and speci®c IR for the different markers. Two representative paraf®n sections per case were stained and assessed with each Ab. The intensity of mGluR immunoreactive staining was evaluated using a scale of 0±3 (0: ±, no; 1: +/±, weak; 2: +, moderate; 3: ++, strong staining). The frequency of mGluR1a-positive axons and mGluR1a-(-5, -2/3) positive astroglial cells [(1) rare; (2) sparse; (3), high] was also evaluated to give information about the relative number of mGluR-positive axonal or astroglial structures within the multiple sclerosis tissue.
The product of these two values (intensity and frequency scores) was taken to give the overall score (total score) shown in Fig. 3 .
Results
Details of multiple sclerosis and control cases
The clinical features of the 12 multiple sclerosis cases included in this study are summarized in Table 1 . At death, all multiple sclerosis patients had persistent neurological de®cits and the length of multiple sclerosis history ranged from 8 to 34 years (mean: 19.4 years). In 10 patients, a secondary progressive (SP) disease course was observed, while two patients had the primary progressive (PP) form of multiple sclerosis.
None of the control subjects had confounding neurological or neuropathological abnormalities.
Metabotropic glutamate receptor expression in multiple sclerosis brain tissue
To investigate the possible changes of neuronal and glial mGluR expression in multiple sclerosis brain, we performed an immunocytochemical study for both group I (mGluR1a, mGluR5) and group II (mGluR2/3) receptors on active, chronic active and chronic inactive lesions. We also examined normal appearing multiple sclerosis tissue for changes in IR that are independent of the acute in¯ammatory process associated with demyelination.
In multiple sclerosis cortical grey matter, the cellular pattern of mGluR1a, mGluR5 and mGluR2/3 was similar to that observed in the control specimens and to that reported previously for human control cerebral tissue (Ong et al., 1998; Oka and Takashima, 1999; Aronica et al., 2001b; .
However, in the multiple sclerosis lesions and in the NAWM, the mGluR expression levels, as well as the pattern of mGluR IR differed from those in control tissue.
Changes in mGluR1a expression pattern: axonal immunoreactivity
In agreement with previous observations in human control specimens (Ong et al., 1998; Aronica et al., 2001b) , mGluR1a IR was present mainly in neurons with a diffuse somatodentritic distribution and an occasionally punctate labelling in the cellular membrane (Fig. 1A) . mGluR1a IR was not detected in glial cells in control cortex (Fig. 1A) and subcortical white matter (Fig. 1B) . In addition, axonal staining was not observed in control brain (Fig. 1A and B) . The overall pattern of staining in multiple sclerosis cortex tissue was comparable with that observed in control tissue (Fig. 1C) . In contrast, in the NAWM of the six multiple sclerosis specimens studied, we observed axonal mGluR1a IR ( Fig. 1D and E; Table 2 ). As previously described, axonal pathological changes in multiple sclerosis tissue can be detected using Abs against non-phosphorylated neuro®la-ments (the SMI-32 antibody; Trapp et al., 1998) . Triple immunolabelling studies showed that some myelinated SMI-32-positive axons in NAWM of multiple sclerosis specimens displayed mGluR1a labelling (Fig. 1E) .
Axonal localization of mGluR1a was also observed in demyelinated areas. Both active and chronic active lesions contained axons with variable amounts of mGluR1a (Figs 1F±I and 3A; Table 2 ). In the borders of active multiple sclerosis lesions, triple-labelling experiments involving Abs to mGluR1a, MOG and SMI-32 revealed the presence of mGluR1a IR in both partially and completely demyelinated SMI-32-positive axons (Fig. 1H and I) . Although not all SMI-
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Page 5 of 12 32-positive axons were positive for mGluR1a (Fig 1E) , no mGluR1a IR was detected in axons stained with Abs to phosphorylated neuro®laments (the Abs 2F11 and RT97; not shown). Double-labelling of sections with Abs to mGluR1a and b-APP (a molecule enriched in axons with a disturbance in axonal transport; Ferguson et al., 1997; Kornek et al., 2000; Bitsch et al., 2000; Kuhlmann et al., 2002) showed colocalization in some axons (Fig. 1G) .
Changes in mGluR immunoreactivity in glia
All multiple sclerosis lesions examined showed prominent astrogliosis. As previously described (Hulshof et al., 2002) , GFAP-positive astrocytes were evenly distributed throughout the demyelinated area in both active lesions and chronic active plaques. Reactive astrocytes were large cells and displayed an increased expression of vimentin and GFAP (Figs 1J±L and 2C±G) .
In agreement with our previous observations in human brain tissue (Aronica et al., 2000 (Aronica et al., , 2001b (Aronica et al., , 2002 , mGluR5 and mGluR3 were the two main mGluR subtypes expressed by astrocytes, in both physiological and pathological conditions. Control specimens contained weak to moderate mGluR5-and mGluR2/3-positive astroglial cells, most notably in the subcortical white matter ( Fig. 2A and B) . A diffuse upregulation of mGluR5 and mGluR2/3 IR was, however, observed in astrocytes present in both acute and chronic active multiple sclerosis lesions ( Fig. 2C and D) . The vast majority of the GFAP/vimentin-positive reactive astrocytes showed strong membranous and cytoplasmic staining for both receptor types (Fig. 2E±G) . No detectable mGluR1a IR was observed in glial cells of control cortex and white matter ( Fig. 1A and B) . However, mGluR1a IR was observed in a subpopulation of reactive astrocytes present in demyelinated areas (Fig. 1J±L) . Figure 3B±D shows the distribution of mGluR astroglial IR (total) score in control and multiple sclerosis tissue.
The in¯ammatory response in multiple sclerosis also involves cells of the microglial/macrophage lineage. Such cells are thought to play key regulatory and pathophysiological roles in the pathogenesis of this disorder (Carson, 2002) . In control human brain, no detectable mGluR-1, -5 and -2/3 IR was observed in cells with the morphology of resting microglia [Figs 1A and B, and 2A and B; Aronica et al., 2001a) . Since mGluRs are expressed in microglial cells activated in culture (Biber et al., 1999; Taylor et al., 2002) , we performed an immunolabelling with Abs to HLA-DP, DQ, DR antigens on chronic active multiple sclerosis lesions containing microglial/macrophage lineage cells at different stages of activation. mGluR2/3 IR, and to a lesser extent mGluR1a IR, was detected in a population of cells with an amoeboid (macrophage-like) morphology, but not in cells with a rami®ed morphology (Figs 1M and 2I) . No labelling with Abs to mGluR5 was observed in cells of the microglial/ macrophage lineage (Fig. 2 H) .
Discussion
The present study provides information about the occurrence of changes in glutamatergic transmission in tissue from multiple sclerosis patients who died during the chronic progressive stage of the disease. In particular, we provide evidence that the expression of mGluRs in multiple sclerosis lesions and NAWM is signi®cantly altered compared with control tissue. The ®ndings can be summarized as follows: (i) in contrast to the expression pattern in normal brain, strong axonal mGluR1a IR was observed in NAWM and in active and chronic multiple sclerosis lesions; and (ii) within the multiple sclerosis lesions, we observed an increase in the astroglial expression of mGluR5 and mGluR2/3, and, in a subpopulation of reactive cells, also of mGluR1a. mGluR1a and mGluR2/3 IR were also detected in cells of the microglial/macrophage lineage with an amoeboid morphology.
Axonal mGluR1a immunoreactivity in multiple sclerosis brain
The physiological actions of mGluRs are intimately linked to their proper localization in neurons. This is of particular interest in relation to the presence of substantial axonal abnormalities in multiple sclerosis (Kornek and Lassmann, 1999) . Axonal pathological changes are already present in the earliest phases of the disease (Ferguson et al., 1997; Trapp et al., 1998; Bitsch et al., 2000 Bitsch et al., , 2001 and have been correlated with disease progression (Ferguson et al., 1997; Kalkers et al., 2001; Wujek et al., 2002) and cognitive decline (Comi et al., 1993; Leocani and Comi, 2000; Edwards et al., 2001) . Targeting of mGluR1 to dendrites and axons appears to be controlled by alternative splicing in transfected primary neurons (Stowell and Craig, 1999; Francesconi and Duvoisin, 2002) . mGluR1a has a predominantly somatodendritic localization in many brain regions (Martin et al., 1992; Baude et al., 1993; Koulen et al., 1997) .
In agreement with this, neurons were labelled with mGluR1a in their somato-dentritic compartment in our study, and no detectable axonal IR was observed in control subcortical white matter.
In multiple sclerosis tissue, we report a change in the IR pattern of mGluR1a as expression is now also observed in axons. The pattern of mGluR1a IR in multiple sclerosis points to axonal changes in the centre of multiple sclerosis lesions and in the NAWM surrounding the plaques. The presence of abnormal axonal mGluR1a expression in NAWM is in line with magnetic resonance spectroscopy and neuropathological studies indicating that the spectrum of axonal pathology is wider than previously recognized (Fu et al., 1998; De Stefano et al., 1999; Tourbah et al., 1999; Bjartmar et al., 2001; Bergers et al., 2002; Giordana et al., 2002) . Interestingly, the mGluR1a axonal immunopositivity was associated with the presence of non-phosphorylated neuro®lament epitopes as assessed by staining with the SMI-32 antibody, a marker for axonal damage (Trapp et al., 1998) .
mGluR IR did not co-localize with myelin and appeared to be distributed evenly within axons. Because of the use of autopsy tissue with the relatively long post mortem time of the tissue, it was not possible to carry out an immunogold electron microscopic study to determine the precise localization of mGuRa within axons. Nonetheless, it is likely that the receptor protein molecules detected in axons in affected multiple sclerosis tissue were being transported from the cell soma to the axonal terminals. Previous electron microscopic studies on rapidly ®xed biopsy control brain tissue have indicated that the IR of group I mGluRs is expressed primarily postsynaptically, although some labelling was also detected in axonal terminals (Ong et al., 1998; Wang et al., 2000; Hubert et al., 2001) . The most likely explanation for the presence of mGuR1a axonal IR in multiple sclerosis tissue is accumulation due to a disturbance in axonal transport, as appears to be the case for a subunit of voltage-gated calcium channels (Kornek et al., 2001) . In our study, the axonal staining of mGluRa also shows a preferential localization in damaged axons, as evidenced by the presence of b-APP, which is a sensitive and early marker for impaired axonal transport (Ferguson et al., 1997; Bitsch et al., 2000; Kornek et al., 2000; Kuhlmann et al., 2002) .
The data from several studies support a crucial contribution of mGluR1a to synaptic transmission in both physiological and pathological conditions (for a review see Bordi and Ugolini, 1999) . Changes in the expression of mGluR1a protein have been reported in association with aberrant axonal organization, and in response to deafferentation Blumcke et al., 2000) . The axonal mGluR1a IR observed in our study (both in lesion areas and in NAWM) may re¯ect diffuse multiple sclerosis axonal pathology, involving both local axons (damaged due to processes of demyelination and in¯ammation) and axons localized distantly from the focus of demyelination (damaged due to deafferentation).
Whether the changes in mGluR1a staining pattern described in this study contribute to the evolution of multiple sclerosis lesions is unclear, as both toxic and neuroprotective effects have been reported (reviewed in Bordi and Ugolini, 1999) . Thus, upregulation of mGluR1a in multiple sclerosis tissue could indicate an attempt to protect neurons from chronic excitotoxic injury. Recent data have suggested that group I mGluRs may limit oligodendrocyte progenitor cell degeneration during acute brain insults (Kelland and Toms, 2001) .
Our study is a descriptive one and we were therefore not able to assess the functional consequences of the axonal expression of mGluR1a. Further research in animal models of multiple sclerosis is clearly needed in order to elucidate the functional implication of changes in mGluR expression in the pathogenesis of the disorder.
Glial mGluR immunoreactivity in multiple sclerosis lesions
Strong expression of both group I and group II mGluRs in glial cells with the morphology of reactive astrocytes was observed in all of the active and chronic active multiple sclerosis lesions included in our study. This is essentially in agreement with previous reports showing that mGluR2/3 and mGluR5 are overexpressed in human reactive glial cells (Aronica et al., 2001a, b) . As previously shown, both membranous and cytoplasmic mGluR staining was observed in reactive astrocytes (Aronica et al., 2000 (Aronica et al., , 2001a (Aronica et al., , b, 2002 . The presence of an intracellular pool of group I mGluR has also been shown by immunogold labelling electron microscopic studies in normal biopsy brain tissue (Hubert et al., 2001) . This may represent a reserve pool important for mGluR functions. Although hours are needed for new receptors to be synthesized and transported to the membrane, it appears that only minutes are required for intracellular receptors to be incorporated into the cell's membranes (Szekeres et al., 1998) .
Whereas virtually all reactive astrocytes displayed mGluR5 and mGluR2/3 IR, the expression of mGluR1a was observed in only a subpopulation of reactive astrocytes. Whether this re¯ects different physiological functions for mGluR subtypes within the glial scar or re¯ects the presence of distinct subsets of astrocytes in multiple sclerosis lesions (Holley et al., 2002) is still unclear. Activation of mGluR subtypes can regulate glial cell function and their interaction with neurons (Winder et al., 1996; Cartmell and Schoepp, 2000) . From our study using ®xed material, it cannot be concluded whether the detected proteins were functionally active. However, cultures of rat and human astrocytes grown in conditions which result in the upregulation of the expression of mGluR mRNAs and proteins mimic the morphological changes of reactive glial cells observed in vivo, and this has been associated with increased receptor functions (Miller et al., 1995b; Aronica et al., 2002) .
The potential role of astrocytes in the initiation, maintenance and regulation of immune responses in multiple sclerosis has been a matter of debate for many years (Lee and Brosnan, 1997; Aschner, 1998) . Recent evidence indicates that astrocyte-mediated immune responses are regulated through activation of different mGluR subtypes (Bruno et al., 1998; Besong et al., 2002; E. Aronica, A.J.Rozemuller, J.A.Gorter, B.Yankaya and D.Froost, unpublished observations) . Activation of group I and II mGluRs has also been shown to regulate glial cell proliferation differentially (Ciccarelli et al., 1997; E. Aronica, A.J.Rozemuller, J.A.Gorter, B.Yankaya and D.Froost, unpublished observations) and glial glutamate transporter protein expression in rat and human astrocytes in culture (Aronica et al., 2002) .
Although cultured microglial cells have been shown to express mGluRs (Biber et al., 1999; Taylor et al., 2002) , no information is available about the in vivo mGluR expression in human microglial/macrophage lineage cells under pathological conditions. In the present study, we provide evidence that mGluR2/3 and, to a lesser extent also mGluR1a, are expressed in a subset of cells of the microglial/macrophage lineage in multiple sclerosis lesions. The expression of group II mGluRs in cells of the microglial/macrophage lineage in multiple sclerosis tissue is in agreement with a recent study showing functional mGluR2/3 receptors in microglia grown in vitro (Taylor et al., 2002) .
Taken together, our ®ndings suggest that changes in mGluR expression may be of relevance to glial function and glial±neuronal communication in multiple sclerosis tissue. Speci®c agonists and antagonists of mGluR subtypes are available and currently are used to evaluate the function of mGluRs in several pathological conditions (Bordi and Ugolini, 1999; Besong et al., 2002) . mGluR subtypes may thus represent an interesting pharmacological target for experimental therapeutic interventions in multiple sclerosis.
